Sales of Zecuity Migraine Skin Patches Halted

Share this content:
Sales of Zecuity Migraine Skin Patches Halted
Sales of Zecuity Migraine Skin Patches Halted

TUESDAY, June 14, 2016 (HealthDay News) -- Sales of the migraine treatment skin patch Zecuity (sumatriptan iontophoretic transdermal system) have been halted after patients reported suffering burns and scars where the patches were applied, Teva Pharmaceutical says.

The Israel-based company also said consumers with the disposable battery-powered patches should stop using them, the Associated Press reported.

The patch is designed to deliver a dose of medicine via a single-use, battery-powered patch that is wrapped around the upper arm or thigh. But some users have developed severe redness, skin discoloration, cracked skin, and pain where patches were applied, according to the U.S. Food and Drug Administration.

Teva said it is recalling the patches and working with the FDA to determine the cause of the skin reactions, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Factors ID'd to Predict Fatty Liver in Obese Teens

Factors ID'd to Predict Fatty Liver in Obese ...

African-American obese teens more susceptible to fatty liver effects on glucose metabolism

Patients Prefer Doctors Who Engage in Face-to-Face Visits

Patients Prefer Doctors Who Engage in Face-to-Face Visits

Patients perceive F2F physicians as more compassionate and better communicators

Flexible Sigmoidoscopy Cuts CRC Incidence, Mortality in Men

Flexible Sigmoidoscopy Cuts CRC Incidence, Mortality in Men

Absolute risks for colorectal cancer, CRC death not reduced for screening group vs. controls in women

is free, fast, and customized just for you!

Already a member?

Sign In Now »